Described is a recombinant vaccine against porcine epidemic diarrhoea (PED), which comprises a viral vector having an inserted exogenic nucleotide sequence that encodes antigenic sites of PED virus type 2, and a pharmaceutically acceptable vehicle, excipient and/or adjuvant, wherein the vaccine is designed to generate an immune response in pigs without being combined with other vaccines or variants of PED virus type 2.
An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and/or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-CoV-2 exogenous nucleotide sequence inserted,
CONSEJO NACIONAL DE HUMANIDADES, CIENCIAS Y TECNOLOGIAS (Mexico)
Inventor
Lozano Dubernard, Bernardo
Soto Priante, Ernesto
Sarfati Mizrahi, David
Chagoya Cortes, Hector Elias
Lopez Macias, Constantino Iii Roberto
Palese, Peter
Garcia-Sastre, Adolfo
Krammer, Florian
Sun, Weina
Torres Rojas, Martha
Abstract
A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity.
A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity.
A live or inactivated recombinant vaccine against COVID-19 comprising a viral vector and vehicle, pharmaceutically acceptable adjuvant and/or excipient, characterised in that the viral vector is a virus capable of generating a cellular immune response and has an exogenous nucleotide sequence from SARS-CoV2 inserted.
Described is a recombinant vaccine, active or inactivated, against COVID-19, which comprises a Newcastle's disease viral vector and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, the vaccine being characterised in that the viral vector is a virus capable of generating a cellular immune response and has an inserted exogenic SARS-CoV-2 nucleotide sequence.
Described is a recombinant vaccine, active or inactivated, against COVID-19, which comprises a Newcastle's disease viral vector and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, the vaccine being characterised in that the viral vector is a virus capable of generating a cellular immune response and has an inserted exogenic SARS-CoV-2 nucleotide sequence.
The invention relates to a recombinant vaccine comprising a vector of avian adenovirus serotype 9 (FAdV-9) with an inserted exogenous sequence of nucleotides coding for an antigen of a disease of interest and replacing the non-essential region of the genome of the adenovirus; and a pharmaceutically acceptable vehicle, adjuvant and/or excipient; where the exogenous sequence of nucleotides is between the nucleotides 491-2782. The vector of this recombinant vaccine is stable when it is produced at an industrial level. Likewise, the recombinant vaccine, even when administered in combination with a vaccine against Marek's disease, produces a suitable immune response that is not affected by the interference caused by said vaccine against Marek's disease nor does the Marek's vaccine inactivate the vaccine according to the invention. This recombinant vaccine allows the barrier of the maternal antibodies to be broken or avoided, inducing a suitable immune response.
A live or inactivated recombinant vaccine is described, comprising a viral vector and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, wherein the viral vector is capable of generating a cell immune response due to an increased alpha and/or gamma interferon production, and is capable of a quick replication, and it has inserted a nucleotide sequence of the ORF 5 and ORF 6 from PRSS.
A live or inactivated recombinant vaccine is described that comprises a viral vector and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, which is characterized in that the viral vector is a virus capable of generating a cellular immune response owing to an increased production of alpha and/or gamma interferon and capable of replicating rapidly, and a PRRS ORF 5 and ORF 6 nucleotide sequence is inserted therein.
A vaccine is described comprising an inactivated viral vector having inserted therein an exogenous nucleotide sequence encoding for a disease of interest, together with a pharmaceutically acceptable vehicle, adjuvant or excipient, providing due protection against the disease of interest through use of a concentration of the viral vector similar to that required for an active virus vaccine based on the same viral vector. Principally viral vectors of paramyxovirus or adenovirus are described.
A combination is described that has coccidiocidal effects and is composed of toltrazuril and trimethoprim. Also described are veterinary compositions in which said combination is used, wherein the veterinary compositions have a potentiated effect that enables birds to recover more rapidly and to have fewer disease sequelae, and there is no precipitation of the active ingredients in the combination when those ingredients are used with hard water.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
patents
